What is Regeneron?
Regeneron is a leading biotechnology company dedicated to the discovery, development, and commercialization of innovative medicines for serious diseases. Leveraging advanced science and proprietary technologies, the company aims to create life-changing treatments for a range of conditions, including cancer, eye diseases, inflammatory disorders, and rare genetic diseases. Its commitment to scientific rigor and patient-centric solutions positions it as a key player in the biopharmaceutical landscape.
How much funding has Regeneron raised?
Regeneron has raised a total of $666.1M across 3 funding rounds:
Stock Offering
$91.4M
Stock Offering
$174.7M
Debt
$400M
Stock Issuance/Offering (1991): $91.4M with participation from Undisclosed
Stock Issuance/Offering (2010): $174.7M led by Undisclosed
Debt (2011): $400M supported by Undisclosed
What's next for Regeneron?
With a substantial total funding of $666.1M and recent undisclosed investment, Regeneron is strategically positioned for continued expansion and research acceleration. The company's focus on developing novel therapies for complex diseases suggests a trajectory aimed at addressing unmet medical needs and capturing significant market share. Future developments are likely to involve further clinical trials, pipeline expansion, and potential strategic partnerships to bring its innovative treatments to a global patient population.
See full Regeneron company page
